Increlex® (mecasermin [rDNA origin])

Overview | Product information | Accredo services | Contact team

Increlex is used in the treatment of short stature caused by severe primary IGF-1 deficiency.

Primary IGF-1 deficiency (Primary IGFD) occurs in children who are very short for their age because their bodies do not make enough IGF-1, a naturally occurring hormone that plays a central role in growth and metabolism. Primary IGFD can be caused by abnormalities of either the growth hormone receptor or the growth hormone signaling pathway.

Learn more about growth hormone therapy.

Increlex is recombinant human IGF-1 formulated as a liquid and administered by subcutaneous injection.

Referral Form – Pediatric Indication Adult Indication

Other Resources:

Increlex.com

Tercica.com